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Abstract: There is a growing understanding of the pathophysiology of secondary 
hyperparathyroidism (SHPT) and a recent emergence of new agents for SHPT treatment in 
patients with advanced kidney disease. At the same time, appreciation that mineral metabolic 
derangements promote vascular calciﬁ  cation and contribute to excess mortality, along with 
recognition of potentially important “non-classical” actions of vitamin D, have prompted the 
nephrology community to reexamine the use of various SHPT treatments, such as activated 
vitamin D sterols, phosphate binders, and calcimimetics. In this review, the evidence for treat-
ment of SHPT with calcimimetics and vitamin D analogs is evaluated, with particular consider-
ation given to recent clinical trials that have reported encouraging ﬁ  ndings with cinacalcet use. 
Additionally, several controversies in the pathogenesis and treatment of SHPT are explored. 
The proposition that calcitriol deﬁ  ciency is a true pathological state is challenged, the relative 
importance of the vitamin D receptor and the calcium sensing receptor in parathyroid gland 
function is summarized, and the potential relevance of non-classical actions of vitamin D for 
patients with advanced renal disease is examined. Taken collectively, the balance of evidence 
now supports a treatment paradigm in which calcimimetics are the most appropriate primary 
treatment for SHPT in the majority of end stage renal disease patients, but which nevertheless 
acknowledges an important role for modest doses of activated vitamin D sterols.
Keywords: secondary hyperparathyroidism, vitamin D, vitamin D receptor, calcium sensing 
receptor, calcimimetics, kidney disease
Introduction
Several cardinal ﬁ  ndings over the past decade have thrust derangements of mineral 
metabolism to the forefront of nephrology. Studies demonstrating the association of 
phosphorous with mortality in end stage renal disease (ESRD) patients,1,2 the preva-
lence of vascular calciﬁ  cation even in young ESRD patients,3 and the association of 
calcium-based binders with increased vascular calciﬁ  cation relative to non-calcium 
based binders4–7 have prompted a re-examination of traditional therapies for secondary 
hyperparathyroidism (SHPT) of advanced renal disease.
Accompanying increased awareness of the importance of mineral metabolic 
dysregulation have been numerous clinical and scientiﬁ  c advancements. The develop-
ment and introduction of calcimimetics for the treatment of SHPT stands as a major 
clinical milestone. Calcimimetics, which are allosteric modulators of the calcium 
sensing receptor (CASR), have rapidly achieved widespread use in ESRD patients 
with SHPT. In parallel, there have also been major advancements in understanding 
the pathogenesis of SHPT, with a greater appreciation of the biological functions 
of the CASR, the vitamin D receptor (VDR), the regulation of 1,25(OH)2 D pro-
duction and metabolism by the 1α-hydroxylase/24-hydroxylase (Cyp17b1/Cyp24) International Journal of Nephrology and Renovascular Disease 2008:1 6
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enzyme system, and the role of ﬁ  broblast growth factor-23 
(FGF23), the principle phosphaturic factor. Additionally, 
there is growing interest in potential “non-classical” actions 
of vitamin D, ie, those actions beyond its traditional role in 
the maintenance of mineral homeostasis. Unfortunately, the 
clinician’s success in reaching targets for control of calcium 
(Ca), phosphate (P), calcium × phosphorous product (Ca × P), 
and parathyroid hormone (PTH) remains suboptimal.
In this review, we explore in detail the body of the evidence 
for treatment of SHPT with both calcimimetics and vitamin 
D analogs, also known as activated vitamin D compounds, 
vitamin D sterols, or calcitriol analogs, and discuss the clini-
cal study evidence as well as the experimental basis for these 
treatments. We also consider several emerging controversies 
with direct relevance to SHPT treatment, speciﬁ  cally (1) 
whether reduced 1,25(OH)2 D in chronic kidney disease 
(CKD) is pathological condition requiring treatment or an 
adaptive response to decreased renal function, (2) whether the 
CASR or the VDR is relatively more important in parathyroid 
gland (PTG) function, and (3) whether “non-classical” actions 
of vitamin D have relevance for patients with advanced kidney 
disease. We conclude with a conceptual framework for the 
treatment of SHPT in end stage renal disease (ESRD).
Review criteria
A PubMed search of English-language articles from 1988 to 
the present was undertaken. The search strategy utilizing a 
ﬁ  rst term of “calcimimetics”, “cinacalcet”, “calcium sensing 
receptor”, “vitamin D”, “vitamin D receptor”, “FGF23”, or 
“ﬁ  broblast growth factor”, coupled by the operator AND 
with a second term of “secondary hyperparathyroidism”, 
“end stage renal disease”, “chronic kidney disease”, “chronic 
kidney failure”, or “chronic renal failure.” Original reports as 
well as reviews were examined. For all reviews, references 
to original reports were sought. Bibliographies of each report 
were examined for additional relevant articles not captured 
by the initial search strategy. This search strategy was aug-
mented by hand-searches for publications of interest in the 
authors’ personal libraries.
Discussion
What evidence exists that cinacalcet 
improves mineral metabolic control 
in SHPT?
A relatively large number of clinical studies have been 
undertaken to investigate the effects of cinacalcet on the control 
of SHPT in ESRD patients. There have been eight published 
randomized controlled trials (RCTs) plus the ACHIEVE trial, 
which is currently in submission. Initial trials were designed 
to test the effects of cinacalcet when added to standard-of-care 
therapy (consisting of either no treatment other than oral phos-
phorous binders or, much more commonly, vitamin D analogs), 
while later trials utilized designs in which cinacalcet was tested 
in combination with low-dose vitamin D analogs against 
higher-dose vitamin D “monotherapy.” More recently, ﬁ  ve 
“single-treatment-arm” studies, in which cohorts of subjects 
were compared to themselves pre- and post-treatment with 
cinacalcet, have been published. While not true RCTs, these 
latter studies provide invaluable real-world clinical insights.
Randomized controlled trials of cinacalcet
In 2002, the ﬁ  rst evidence that cinacalcet lowered PTH lev-
els emerged.8 When cinacalcet, then known as AMG 073, 
or placebo was given to 30 hemodialysis (HD) patients for 
8 days, treated subjects demonstrated a statistically signiﬁ  -
cant improvement in PTH levels, measured as percent change 
from baseline. Calcium, P and Ca × P also fell, although 
p-values were not reported. Soon thereafter, Quarles et al9 and 
Lindberg et al10 reported on true placebo-controlled RCTs 
of cinacalcet. Both studies consisted of 12-week titration 
phases and 6-week assessment phases. Quarles et al studied 
71 HD patients, approximately two-thirds of whom were 
taking vitamin D analogs, and found that cinacalcet treat-
ment resulted in robustly signiﬁ  cant decreases in PTH, Ca, 
and Ca × P, when measured as percent change from baseline. 
Phosphorus did not change. Vitamin D analog use did not 
affect the results, because when subjects were divided into 
those who had an increase, decrease, or no change in vitamin 
D analog dose over the course of the study, reductions in 
percent change in PTH remained signiﬁ  cant (p = 0.008). The 
study by Lindberg et al involving 78 HD patients found that 
cinacalcet-treated subjects achieved statistically-signiﬁ  cant 
improvements in percent change of PTH, Ca, P, and Ca × P 
(p  0.001 for all). Again, about two-thirds of subjects were 
using vitamin D analogs at the start of the study; these inves-
tigators used logistic regression to determine that its use was 
not associated with reductions in PTH.
Larger studies, with increased power to examine multiple 
biochemical outcomes, were subsequently conducted. 
Lindberg et al studied 395 HD and peritoneal dialysis (PD) 
patients, and found that cinacalcet was associated with 
statistically-signiﬁ  cant decreases in both mean and percent 
change of PTH, Ca, and Ca × P, as well as the percent 
of subjects achieving PTH  300 pg/mL and Ca × P  
55 mg2/dL2.11 The largest study of cinacalcet versus placebo International Journal of Nephrology and Renovascular Disease 2008:1 7
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was that of Block et al,12 which consisted of two identical 
parallel trials (in North America and Europe) enrolling a 
total of 741 HD patients. The percent of subjects reach-
ing PTH  250 pg/mL (the primary endpoint), the percent 
change in PTH from baseline, and the difference in ﬁ  nal mean 
PTH value were all statistically signiﬁ  cant, as were decreases 
in Ca and P. In stratiﬁ  ed analyses of sex, age, race (African 
versus European descent), dialysis duration, strata of initial 
PTH (using cutoffs of 300, 500, and 800 pg/mL), and use of 
vitamin D analogs, cinacalet was superior in the attainment 
of the primary endpoint.
All of the above studies were designed as “real world” 
studies in which providers had the liberty to adjust vitamin D 
analog doses as they saw ﬁ  t, albeit according to a study-spe-
ciﬁ  c standardized protocols. This was done to allow the sub-
jects to continue to receive standard-of-care therapy, which 
at that time included vitamin D analogs for SHPT. In each 
of the studies, vitamin D analog doses remained relatively 
constant within each arm as well as comparable across arms 
at the baseline and ﬁ  nal timepoints. While this type of design 
allows for the isolation of the effects of cinacalcet, it does 
not permit a determination of whether one agent is more 
effective than another for control of SHPT, or yield insights 
as to whether one therapy (cinacalet) could replace another 
(vitamin D analogs) as primary therapy.
A recent metaanalysis by Strippoli et al formally examined 
the above studies.13 These investigators concluded that, for 
absolute levels of PTH, Ca, P, and Ca × P, cinacalcet resulted 
in signiﬁ  cantly different outcomes relative to placebo. How-
ever, several other RCTs were either not included in the 
above analysis, or were published subsequent to it. Martin 
et al randomized 410 HD patients to cinacalcet or placebo 
and found that cinacalcet-treated subjects had statistically-
significant decreases in several biochemical endpoints, 
including percent change in PTH, mean concentrations of 
PTH, Ca, P, and Ca × P, and the proportion of subjects 
reaching PTH  250 pg/mL.14 The percentage of subjects 
receiving vitamin D analogs was no different between 
groups at baseline and at study completion. Fukugawa et al 
used lower doses of cinacalcet (100 mg/day being the high-
est allowable dose, versus 180 mg for most other trials) to 
randomize Japanese patients to cinacalet versus placebo and 
found signiﬁ  cant decreases in Ca, P and Ca × P, as well as a 
signiﬁ  cantly greater number of subjects reaching 30% reduc-
tions in PTH and PTH  250 pg/mL.15 Vitamin D analog 
use at baseline was reported to have no effect on attainment 
of goals, but a full description of activated vitamin D usage 
in the two groups was not reported.
Only two studies, to our knowledge, have attempted to 
minimize vitamin D analog dose in an attempt to determine 
whether cinacalcet might be used in lieu of, rather than in 
addition to, vitamin D analogs. Messa et al recently published 
the results of the OPTIMA study.16 These investigators delib-
erately attempted to titrate down vitamin D analog dose, while 
preserving the provider’s ability to dose as they saw ﬁ  t. A total 
of  552 subjects were enrolled in an open-label study. These 
authors found cinacalcet to be superior in achieving goals 
for PTH (300 pg/mL), Ca (9.5 mg/dL), P (5.5 pg/mL), 
Ca × P (55 mg2/dL2), and Ca × P plus PTH endpoints. While 
there was only a modest relative dose change in vitamin D 
between the groups (a 6% decrease in the cinacalcet group 
versus a 14% increase in the vitamin D-alone group), in the 
subgroup of subjects receiving vitamin D analogs at baseline 
(68% of the total study sample), there was a 22% decrease 
in relative vitamin D analog dose in the cinacalcet arm as 
opposed to a 3% increase in the control arm; whether this 
was statistically signiﬁ  cant was not reported. Finally, the 
ACHIEVE study, currently under peer review, randomized 
approximately 178 HD patients to cinacacet and low-dose 
vitamin D analogs or vitamin D alone. This study showed 
that cinacalcet-treated subjects resulted in signiﬁ  cantly higher 
numbers of subjects reaching targets for PTH, P, and Ca × P 
KDOQI targets, although there was more hypocalcemia in 
the cinacalcet arm.
The majority of evidence now demonstrates that cinacalcet 
is an extremely effective agent for the suppression of PTH, and 
that it has a clear role in therapy for SHPT. Such conclusions 
emerge readily upon collectively reading individual reports, 
while conﬁ  rmation of this is provided in the ﬁ  ndings of the 
recent metaanalysis. Even more signiﬁ  cantly, the OPTIMA 
and ACHIEVE studies provide convincing evidence that cina-
calcet can have a vitamin D analog-minimizing effect while 
achieving important clinical targets, suggesting that cinacalcet 
is a viable candidate for primary treatment for SHPT.
Other clinical studies of cinacalcet
As cinacalcet is increasingly used in clinical practice, other 
investigators are reporting on their long-term experiences 
with this agent, particularly in situations where cinacalcet-
based regimens have supplanted vitamin D analog-based ones 
in clinical practices. Moe et al reported on 59 subjects who 
completed 100 weeks of an open-label trial of cinacalcet.17 
They demonstrated long-term control of PTH, in which the 
level of PTH at 52 weeks was little changed at 100 weeks, 
with PTH at both timepoints being signiﬁ  cantly better than 
at baseline. Sterrett et al reported on 1 year of cinacalcet International Journal of Nephrology and Renovascular Disease 2008:1 8
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use in 210 HD patients, demonstrating a significantly 
greater decrease in percent change of PTH, percent change 
of Ca × P, attainment of PTH  250 pg/mL, and 30% 
reduction in PTH.18
Two recent studies involved paradigms in which deliberate 
attempts were made to reduce vitamin D analog dose. Chertow 
et al examined 72 subjects with elevated Ca × P, all of whom 
were taking vitamin D analogs, in an open-label prospective 
study.19 Subjects had their vitamin D analog dose reduced to 
“physiologic” levels of calcitriol (eg, paricalcitol 2 μg thrice 
weekly) while cinacalcet was initiated and subsequently 
titrated upwards as needed. Percent change in PTH, Ca, P, and 
Ca × P, and percent of subjects reaching Ca × P goal were all 
signiﬁ  cantly greater in the cinacalcet arm (p  0.0001 for all), 
while mean vitamin D dose was halved (and discontinued 
outright in 21% of subjects), demonstrating the ability of 
cinacalcet to “spare” vitamin D analogs. An open-label study 
by Block et al involved 375 subjects in which doses were 
reduced to low levels at study initiation.20 Mean vitamin D 
dose was also halved in this study, and percent change in 
PTH, Ca, P, and Ca × P were signiﬁ  cantly different between 
arms (p  0.0001), again demonstrating that cinacalcet can 
be effective therapy for SHPT even in the face of lowering 
vitamin D dose.
Cinacalcet has also been tested in patients with extremely 
high levels of PTH. Arenas et al treated 28 HD patients with 
refractory SHPT (mean PTH 829 pg/mL), in whom treatment 
with vitamin D analogs was compromised by hypercalcemia 
or hyperphosphatemia, with cinacalcet.21 They observed 
robust decreases in PTH, Ca, and Ca × P product, while P did 
not change. No decrement in vitamin D dose was necessarily 
sought, since the patients were by deﬁ  nition difﬁ  cult to con-
trol with vitamin D analogs alone. After 9 months, all subjects 
achieved PTH  500 pg/mL, demonstrating cinacalcet’s 
usefulness is refractory SHPT.
Finally, in analyses of small single-center cohorts, other 
investigators have studied the effects of changes in treat-
ment protocols. Lazar et al22 and Speigel et al23 initiated new 
cincacalcet-based paradigms, and compared attainment of 
KDOQI Clinical Practice Guideline targets before and after 
conversion of their treatment paradigms. While the studies 
were modest in size (35 and 61 subjects, respectively), 
and statistical power therefore limited, the former study 
demonstrated a signiﬁ  cant increase in subjects attaining 
at least three mineral metabolic targets, and the latter a 
signiﬁ  cant improvement in subjects attaining PTH goals. 
In the former study, the investigators reported that there 
was a 33% increase in subjects administered paricalcitol, 
presumably due to either hypocalcemia or because lowered 
cinacalcet-induced Ca × P permitted reintroduction of 
vitamin D analogs. In the latter study, vitamin D doses did 
not change in the cinacalcet-treated subjects.
Other evidence for beneﬁ  ts of cinacalcet
As reviewed deﬁ  nitively by Brown and MacLeod,24 the 
CASR is found in a variety of tissues. Many of these 
are unlikely to play a major role in mineral metabolism, 
such as the brain, pancreas, bone marrow, pituitary, skin 
(keratinocytes) and breast (ductal cells). However, the CASR 
is found in other locations which may have direct impact 
on mineral metabolism, and, as such, morbidity in dialysis 
patients. Three such tissues are the parathyroid gland (PTG), 
the bone, and the vasculature.
In the PTG, the CASR regulates PTH secretion acutely 
and PTH gene transcription chronically.24,25 It also regulates 
PTG cell growth.26 In both humans with neonatal severe 
hyperparathyroidism27 and in the analogous homozygous casr 
animal knockouts,28 there are increases in PTH, serum Ca, 
and hyperplasia of the PTG, while in uremia-induced SHPT, 
the CASR is downregulated in humans and animals.29–32 As 
reviewed by Drueke at al,33 the effects of calcimimetcs have 
been extensively studied in rodents, where cinacalcet has 
consistently been shown to prevent to development of, or 
mitigate the effects of, PTG hyperplasia.34,35 Cinacalcet has 
even been shown to reverse hyperplasia.35 Calcimimetics 
have also been shown to upregulate the CASR in rodent 
models of renal failure.36
The effects of cinacalcet on calcium-mediated PTH 
release have been examined by de Francisco et al, who studied 
10 subjects with extreme SHPT (mean PTH 1116 pg/mL).37 
Subjects were placed on alternating low-Ca and high-Ca 
dialysate baths to maximally stimulate and suppress the PTG, 
exposed to a mean of 13 weeks of cinacalcet, then tested again 
in the same manner to determine if there was any effect of 
cinacalcet on the PTH release setpoint (the Ca level associated 
with 50% maximal PTH stimulation). Cinacalcet reduced the 
setpoint and the maximal PTH release, an important ﬁ  nding 
because this setpoint may be a marker for the severity of SHPT 
and of PTG mass. More direct, but still rather preliminary, 
evidence of a potential association between cinacalcet and 
PTG histology comes from Lomonte et al.38 These investigators 
examined PTG glands and found that nodular hyperplasia was 
more common in vitamin D analog-treated and in cinacalcet 
plus vitamin D-treated individuals than in individuals treated 
with binders alone. Because no subjects were exposed to 
cincacalcet monotherapy, they relied on linear regression to International Journal of Nephrology and Renovascular Disease 2008:1 9
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attempt to isolate the independent effects of cinacalcet, and 
found that the drug was associated with a signiﬁ  cant increase in 
oxyphil to chief cell ratio. Oxyphil cells have been reported to 
proliferate at a lower rate than chief cells,39 perhaps indicating 
that cinacalcet could slow the histologic progression of SPTH. 
However, the study was small, and the results should be 
considered hypothesis-generating.
Only one report, to our knowledge, has investigated 
the potential effects of calcimimetics in bone histology 
of humans.40 Cinacalet use was associated with improved 
bone histomorphometry. While vitamin D analog use was 
not controlled for, the investigators attempted to minimize 
the dose. Cinacalcet-treated subjects had reduced markers 
of bone turnover and bone turnover rates by histology. 
However, they also experienced improvement in PTH, so 
improvements in bone histology may have been the result of 
better mineral metabolic control, rather than of any speciﬁ  c 
beneﬁ  t attributable to cinacalcet per se.
Of great importance in ESRD patients are the potential 
effects of calcimimetics on the cardiovascular system. In 
vitro models demonstrate that functional CASR is present 
in rat cardiac myocytes.41,42 When such cells were exposed 
to calcium, intracellular inosotol phosphate concentra-
tions increased, while exposure to cinacalcet shifted the 
curve to the left, implicating the CASR in this pathway.42 
Cinacalcet also reduced DNA synthesis in proliferating 
neonatal cardiac myocytes, indicating that the CASR may 
play a role in cardiac hypertrophy.42 The CASR also appears 
to be present in blood vessels. While not all studies have 
demonstrated this,43 several investigators have reported 
the CASR in adventitia44 and endothelium.45,46 In human 
aorta, the CASR agonist spermine increased intracellular 
Ca and NO production.47 Taken together with data showing 
that dietary Ca causes vascular relaxation, it is plausible to 
suggest that the CASR plays a role in vascular relaxation.48 In 
vivo models are also promising in this regard. In the uremic 
rodent model, calcimimetics were associated with decreased 
cardiac remodeling,49 raising the possibility that cinacalcet 
could provide protection against cardiac remodeling and 
vascular calciﬁ  cation in humans.
Whether calcimimetics might demonstrate survival 
beneﬁ  cial effects in ESRD patients though these actions on the 
PTG, bone, or the vasculature, requires much future investigation. 
However, some tantalizing evidence for this possibility has 
recently emerged. In study of 4 similarly-designed trials 
comprising 1184 subjects, Cunningham et al found signiﬁ  cant 
associations between use of cinacalcet and decreased risk 
of parathyroidectomy and cardiovascular hospitalization, 
although not with mortality risk.50 While the study was a 
retrospective and relied on pooled data, it provides intriguing 
preliminary evidence that cinacalcet might be a useful in 
reducing the need parathyroidectomy, and, more profoundly, 
might also have cardioprotective effects.
What evidence exists that vitamin D 
analogs improve mineral metabolic 
control in SHPT?
The clinical trial evidence for the ability of vitamin D analogs 
to improve mineral metabolic parameters is somewhat 
less than that for cinacalcet, which is probably a reﬂ  ection 
that the former’s demonstrable ability to lower PTH allowed 
it to become standard-of-care without evidence from multiple 
RCTs. There have been a few RCTs which have tested the 
efﬁ  cacy of vitamin D analogs versus placebo for treatment of 
SHPT. For example, Martin et al51 and Delmez et al52 tested 
paricalcitol and calcitriol, respectively, against placebo, and 
found signiﬁ  cant improvements in PTH in response to expo-
sure to the activated vitamin D compound. Several trials have 
been designed to test one (ie, a non-selective) agent against 
another (ie, a selective agent) over timeframes ranging from 
a few days53,54 to 32 weeks,55 although longer-term studies of 
cohorts exposed to single agents in non-placebo-controlled 
studies have been conducted over a year or more.56–58 Control 
of mineral metabolic parameters, and not mortality, was their 
principle endpoint.
However, there are been several large observational 
studies that have shown a consistent positive association 
between treatment of ESRD patients with vitamin D analogs 
and survival. Using the Fresenius Medical Care database, 
Teng et al examined over 67,000 HD patients to compare 
the effects of paricalcitol, a selective vitamin D analog, 
with calcitriol, a ﬁ  rst-generation non-selective agent.59 They 
observed an adjusted hazard ratio (HR) of 0.84 (95% con-
ﬁ  dence intervals [CI] 0.79–0.90) for paricalcitol relative to 
calcitriol. In a subsequent study, these investigators investi-
gated whether use of any vitamin D analog provided survival 
beneﬁ  ts relative to no use. Over 50,000 Fresenius Medical 
Care dialysis patients were examined for 2-year survival.60 
They observed a 20% survival improvement for vitamin D 
analogs (HR 0.80, 95% CI 0.76–0.83). The investigators 
used sophisticated statistical techniques, including treatment 
of the exposure as time-dependent (to appropriately credit 
exposure risks and beneﬁ  ts to actual exposure), use of Cox 
regression models augmented by stratum-speciﬁ  c hazard 
ratios, sensitivity analyses to test for consistency of results 
under various assumptions, and, in a secondary analysis, International Journal of Nephrology and Renovascular Disease 2008:1 10
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the relatively novel technique of inverse probability of 
treatment weighting (IPTW), in which subjects are assigned 
a probability of receiving an exposure (vitamin D analogs) in 
a time-dependent fashion. Through these numerous analyses, 
the survival beneﬁ  t attributable to vitamin D analogs was 
generally in the 20% to 27% range; that multiple statistical 
approachs yielded a similar magnitude of beneﬁ  t strengthens 
their conclusions.
Kalentar-Zadeh et al examined over 58,000 incident and 
prevalent HD patients, and also found a signiﬁ  cant survival 
advantage associated with paricalcitol use.61 These inves-
tigators also used time-dependent Cox models, and used 
models adjusted for both case mix (a surrogate for baseline 
comorbidites, to which the authors did not have access) and a 
malnutrition-inﬂ  ammation index created by the authors. This 
study, however, identiﬁ  ed dose-dependent effects of vitamin D 
analogs, such that individuals receiving high (15 μg of 
paricalcitol per week) had worse survival, consistent with 
possible toxic effects of high dose vitamin D analogs. An 
alternative possibility, which cannot be discounted, is that 
patients with refractory SHPT, in whom large doses of 
vitamin D analogs were prescribed as a result, had a much 
higher mortality than those with less ﬂ  orid SHPT. The other 
large study examining this issue was that of Tentori et al who 
studied over 7700 prevalent HD patients from the Dialysis 
Clinics Incorporated database.62 While median followup was 
relatively short (37 weeks), these investigators also found a 
20% improvement in mortality associated with use of any 
vitamin D analog.
Despite this evidence, caution should be used in extrapo-
lating these results too broadly. No technique of statistical 
adjustment is likely to remove all residual confounding, and the 
results could also be explained by confounding by intent (non-
random treatment allocation bias). In many cases, decisions to 
treat or not to treat with vitamin D analogs in ESRD involves 
a physician’s bedside anecdotal knowledge of the patient’s 
medical history and comorbidities, and is unlikely to be fully 
captured by knowledge of either comorbidites (as recorded in 
databases) or through case-mix adjustment. Given the disap-
pointing history of the discordance between observational 
studies and RCTs in the dialysis population, a RCT is needed 
to demonstrate the survival advantage of vitamin D analogs.
Controversies in therapy for SHPT: 
Is there a biologically plausible rationale 
to select one class of agents over another?
In the absence of prospective trials of dialysis patients 
demonstrating whether either calcimimetics or vitamin D 
analogs improve mortality, a variety of other considerations 
should inform prescribing practices. Here we examine several 
controversies in SHPT treatment, including whether reduced 
1,25(OH)2 D in advanced kidney disease is pathological or 
an adaptive condition requiring treatment, whether either 
agent could be expected to have direct effects on PTG func-
tion through their respective receptors, and whether “non-
classical” actions of vitamin D have relevance for patients 
with advanced kidney disease.
Is calcitriol deﬁ  ciency in kidney disease 
a pathological state or an adaptive response?
The focus of the traditional understanding of SHPT has 
centered on diminished renal synthesis of 1,25(OH)2 D. 
According to this view, chronic kidney disease (CKD) 
represents a functional vitamin D-deﬁ  cient state,63,64 resulting 
from the inability of the decreased renal mass to convert 
25(OH) D (calcidiol) to 1,25(OH)2 D (calcitriol). This 
traditional framework has been shaped by an understanding 
of “true” vitamin D-deﬁ  cient states, and holds that impaired 
gastrointestinal Ca absorption results from a reduction in 
1,25(OH)2 D levels, and also results in stimulated PTH 
secretion. PTH has several targets: (1) bone, to increase Ca 
efﬂ  ux; and (2) kidney, to stimulate 1,25(OH)2 D production, 
increase tubular Ca absorption, and inhibit P reabsorption. 
Elevated PTH levels maintain circulating Ca and P levels 
until compensatory mechanisms fail, during which time PTG 
hypertrophy and hyperplasia ensue. The role of diminished 
calcidiol availability is controversial: it may or may not be 
due to nutritional factors,65 dysregulated liver metabolism,66 
or decreased substrate delivery to the kidney resulting from 
low glomerular ﬁ  ltration rate.63 Diminished calcidiol likely 
contributes to decreased 1,25(OH)2 D levels in CKD. This 
view, which centers around the cardinal importance of 
vitamin D, would suggest that primary treatment of SHPT 
should consist of active vitamin D analogs to suppress PTH, 
possibly in conjunction with supplementation by nutritional 
vitamin D calcidiol.
The traditional view that CKD is a state of true vitamin 
D deﬁ  ciency may be challenged by several observations. 
First, phosphate retention in CKD appears to be the initial 
abnormality inciting the development of SHPT. This is 
evidenced by the decreased capacity of the kidney to excrete 
phosphate, as well as the observation that reduction in dietary 
phosphate alone, in proportion to declining GFR, can prevent 
the development of SHPT in models of CKD.67 Second, nutri-
tional vitamin D deﬁ  ciency is more commonly associated 
with hypophosphatemia,68 rather than hyperphosphatemia International Journal of Nephrology and Renovascular Disease 2008:1 11
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resulting from impaired renal phosphate clearance. Third, the 
principal function of the vitamin D/PTH axis is not to prevent 
hyperphosphatemia , but rather to protect the organism from 
hypocalcemia by stimulating bone Ca efﬂ  ux, 1,25(OH)2 D 
production, and renal Ca reabsorption. The role of PTH on P 
excretion is a secondary, mainly designed to excrete the P 
accompanying gastrointestinal Ca absorption and Ca efﬂ  ux 
from the bone. Together, these strongly suggest that elevated 
PTH secretion in both vitamin D deﬁ  ciency and advanced 
kidney disease have more relevance to the maintenance of 
circulating Ca levels than with P homeostasis.
Fourth, there is some evidence of refractoriness to treat-
ment of calcidiol deﬁ  ciency in CKD. While this issue is an 
active area of investigation in which more study evidence 
is likely to come to light, provision of nutritional vitamin D 
supplementation in the form of ergocalciferol to many CKD 
individuals with calcidiol deﬁ  ciency leads to disappointing 
results. Some CKD patients appear refractory to nutritional 
vitamin D supplementation, as evidenced by the difﬁ  culty 
achieving “normal” levels of calcidiol using ergocalciferol 
in these patients. For example, Zisman et al administered 
ergocalciferol to deﬁ  cient stage 3 and 4 CKD subjects accord-
ing to the KDOQI suggested protocol.69 After a long mean 
treatment period of over 7 months, subjects increased their 
calcidiol levels only to the 30 to 35 ng/mL range, with about 
one-third of subjects failing to reach levels 30 ng/mL. In 
another study, insufﬁ  cient and deﬁ  cient stage 3 and 4 CKD 
subjects were treated with an intense ergocalciferol regimen 
(50,000 IU weekly for 12 weeks, then 50,000 IU monthly for 
3 months).70 Calcidiol levels increased from an average of 
16.6 ng/mL to only 27.2 ng/mL, and 45% demonstrated trivial 
increases of calcidiol (5 ng/mL). It is certainly possible that 
ergocalciferol is not the optimal form of nutritional vitamin D 
supplementation. However, while one study demonstrated 
greater success by using cholecalciferol, resulting in a greater 
improvement in calcidiol levels, this was not accompanied 
by a statistically-signiﬁ  cant suppression of PTH.71
The discovery of FGF23, and its function as a 1,25(OH)2 
D counter-regulatory hormone,72,73 provides a new con-
ceptual framework for understanding the pathogenesis 
of SHPT. Made in bone, FGF23 is involved in adaptive 
responses which have evolved to protect the organism 
from hyperphosphatemia and vitamin D intoxication. 
Both PTH and FGF23 have phosphaturic actions, but they 
have opposite effects on 1α-hydroxylase/24-hydroxylase 
enzyme systems: PTH stimulates 1,25(OH)2 D produc-
tion and inhibits its degradation, whereas FGF23 inhibits 
production74–76 and increases degradation. FGF23 acts as a 
“counter-regulatory” hormone, to decrease 1α-hydroxylase 
and increase 24-hydroxylase (diminishing calcitriol levels). 
In this way, the FGF23-bone-kidney axis may be an effector 
of a phosphate “trade-off” that compensates for limited renal 
P excretion. Reduced renal P excretion may be the initial 
stimulus for a cascade of events, in which FGF23-dependent 
suppression of renal 1,25(OH)2 D production is an adaptive 
response, limiting gastrointestinal P absorption, rather than 
a functionally-deﬁ  cient state requiring treatment. Thus, 
small increases in FGF23 are a very early event in CKD 
to maintain neutral P balance.77–79 FGF23 also has direct 
effects on the PTG to suppress PTH secretion,74 which leads 
to the removal of PTH-mediated stimulatory effects on 
1α-hydroxylase, and to further endogenous suppression of 
1,25(OH)2 D production. As such, PTH elevation is almost 
certainly a later event following FGF23-mediated reductions 
in 1,25(OH)2 D.
Therapeutic approaches to SHPT would therefore differ 
depending on which conceptualization of SHPT pathogenesis 
is correct. If kidney disease represents functional calcitriol 
deﬁ  ciency, then administration of vitamin D analogs to 
suppress PTH is rational. However, if P retention leads to 
increases in FGF23, suppression of 1α-hydroxylase, and 
stimulation of 24-hydroxylase leading to a fall of calcitrol 
levels, then the primary treatment of SHPT would be 
P restriction rather than vitamin D analog administration, 
since the latter would serve to increase Ca and P absorption, 
hyperphosphatemia, and further stimulation of FGF23. 
If this is true, it is fair to ask why treatment with vitamin 
D analogs in stage 4 and 5 CKD suppresses PTH without 
raising serum P.80 The answer may be that vitamin D itself 
stimulates production of FGF23 levels, in turn increasing 
phosphaturia in the setting of decreasing renal function. In 
ESRD patients, in contrast, treatment with active vitamin 
D analogs worsens hyperphosphatemia, probably reﬂ  ecting 
the unopposed effect of increase gastrointestinal phosphate 
absorption,62 while cinacalcet results in a slight decrease in 
serum phosphate levels.12,16 The mechanism of this latter 
effect is uncertain, but may be due to a decrement in PTH-
mediated P efﬂ  ux from bone.
What is the relative importance of CASR 
and VDR in regulating PTG function?
The CASR regulates PTH gene transcription and secretion24,25 
and cell proliferation of the PTG.26 In humans with neonatal 
severe hyperparathyroidism27 and, analogously, in homozy-
gous casr knockout mice,28 there are increases in PTH and 
serum Ca, as well as hyperplasia of the PTG, in spite elevations International Journal of Nephrology and Renovascular Disease 2008:1 12
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in circulating 1,25(OH)2 D.33,81–83 In contrast, while ablation 
of the VDR also results in severe hyperparathyroidism, nor-
malization of serum Ca (leading to activation of the CASR) 
is sufﬁ  cient to normalize PTH secretion and suppress PTG 
hyperplasia.84 That calcitriol is ineffective in suppressing 
PTH in the absence of the CASR, while Ca is sufﬁ  cient to 
normalize PTG function in the absence of VDR, is evidence 
that the CASR is the dominant regulator of PTG function. 
The principal direct function of the VDR in the PTG, then, is 
to suppress PTH gene transcription; the VDR has an indirect 
function on the PTG via its actions in the gastrointestinal tract 
to increase Ca absorption and elevate serum Ca levels, which 
serves to affect PTG function via the CASR.
That the CASR appears to have a more dominant role over 
VDR in PTG hyperplasia does not trivialize the role of the 
VDR is unimportant. Complex interrelationships between the 
CASR and VDR exist. Both the CASR29–32 and the VDR85–89 can 
be downregulated in humans and animals with severe SHPT, 
making the gland resistant to treatment with vitamin D analogs. 
In rodent models of renal failure, calcimimetics upregulate 
the CASR.36 There is also data that the VDR upregulates the 
CASR.90–92 While in the setting of adequate Ca the VDR is not 
necessary for the short-term survival of the organism, in the 
setting of more complex environments and over the long-term, 
a physiologically replete vitamin D state may be important.
Putative actions of vitamin D beyond mineral 
metabolism: relevance to patients with kidney disease
There is a growing body of literature on potential non-
classical actions of vitamin D, ie, actions beyond those 
directly involved in mineral metabolism. Much of this data are 
derived from observational studies of individuals with normal 
renal function who are nutritionally vitamin D-deﬁ  ciency 
(and who therefore have presumed impairments of VDR-
dependent signaling), and from studies that investigate the 
extra-renal production of 1,25(OH)2 D and its role in innate 
immunity. Of particular relevance to ESRD patients are the 
putative effects of extrarenal production of 1,25(OH)2 D on 
innate immunity.93 As reviewed by Peterlik et al,94 activated 
vitamin D (calcidiol) is involved in many immune functions, 
such as induction of monocyte chemotaxis,95 macrophage dif-
ferentiation,96,97 upregulation of Fc receptors,98 and production 
of the respiratory burst99 and of nitric oxide.100 Perhaps the 
most compelling evidence for the role of calcidiol emerges 
from studies of tuberculosis, where both in vitro and in vivo 
studies, as well as in epidemiologic investigations, calcidiol 
status is important in defense against this organism.101 While 
tuberculosis is uncommon in ESRD patients in developed 
countries, other types of infections are extremely common; 
whether a state of physiologic 1,25(OH)2 D repletion would 
be a defense against infection is uncertain.
However, in addition to substrate, extrarenal production 
of 1,25(OH)2 D requires activation of Toll-like receptors 
necessary for upregulation of 1α-hydroxylase and downregu-
lation of 24-hydroxylase.93 Given the low levels of peripheral 
conversion of 25(OH) D to 1,25(OH)2
 D,102 it is not clear if the 
extrarenal production of 1,25(OH)2 D has the same signiﬁ  -
cance in the setting of renal failure, where the vitamin D axis 
is suppressed by FGF23, as it does in nutritionally vitamin 
D-insufﬁ  cient patients with normal kidney function.
Also of great potential importance is the possible role 
of vitamin D and its analogs in cardioprotection. Levels of 
calcidiol have been shown to be correlated with insulin sen-
sitivity in epidemiologic studies,103–105 and may be associated 
with the metabolic syndrome. Additionally, there may be 
direct cardioprotective effects of calcitriol on the cardiovas-
cular system, with evidence that calcitriol antagonizes cardiac 
myocyte hypertrophy in rats106 and down-regulates the 
renin-angiotensin system.107 Again, whether these ﬁ  ndings 
have clinical relevance in humans requires further study.
Given the collective body of evidence, 
what therapeutic approaches might be 
most suitable for the treatment of SHPT?
In Figure 1, we illustrate two potential therapeutic approaches 
to SHPT (one calcimimetic-based, the other vitamin D 
analog-based), and list relevant advantages and disadvantages 
of each. The Figure represents less a speciﬁ  c protocol than 
an overall conceptualization of possible treatment strategies. 
Patients with low calcium levels (ie, 8.4 mg/dL) might best 
avoid the potential for cinacalcet-induced hypocalcemia, 
at least until low doses of activated vitamin D compounds 
increase serum calcium to the normal range, while those with 
high serum calcium ought to avoid large doses of activated 
vitamin D compounds. For patients whose calcium levels 
fall within the “acceptable” NKF K/DOQI range, namely 
8.4 to 9.5 mg/dL, the approaches have many similari-
ties. In both, dietary phosphorous restriction is important, 
and oral phosphate binders critical. Non-calcium-based 
binders are generally preferred in either approach, given 
the mounting evidence that non-calcium based binders are 
associated with less vascular calciﬁ  cation4–7,108 and perhaps 
improved survival,109 although the latter ﬁ  nding requires 
replication and extension in true blinded RCTs.
However, the cinacalcet-based approach relies on cal-
cimimetics as the principal agent for PTH reduction, while International Journal of Nephrology and Renovascular Disease 2008:1 13
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Figure 1 Competing therapeutic strategies for treatment of secondary hyperparathyroidism, with advantages and disadvantages.
Abbreviations: PTH, parathyroid hormone; SHPT, secondary hyperparathyroidism.
Secondary hyperparathyroidism: PTH > 300 ng/mL, calcium ) 8.4 and ≤ 9.5 mg/dL, and calcium x phosphorous product < 55 mg2dL2
Calcimimetic-based therapy: a newer approach  Vitamin D analog-based therapy : a traditional approach
Step 1
Dietary counseling on phosphorus restriction
Oral phosphate binders, preferably non-calcium-based; calcium-based
   if calcium falls below 8.4 mg/dL
Escalating cinacalcet doses up to 180 mg daily
Low-dose vitamin D analogs (eg, up to 2 μg paricalcitol,  1 μg 
   doxercalciferol, or 0.5 μg calcitriol intravenously thrice weekly, or oral 
   equivalents)
Step 2
Decrease cinacalcet dose if:
Cinacalcet not tolerated at adequate dose to control PTH
Symptomatic or severe hypocalcemia (? 8.4 mg/dL) despite change
   to calcium-based binders and/or increase in vitamin D analogs dose
Increase vitamin D analogs dose if:
PTH levels not sufficiently reduced on maximally tolerated dose of 
   cinacalcet
Hypocalcemia present despite calcium-based binders
Step 1
Dietary counseling on phosphorus restriction
Oral phosphate binders, preferably non-calcium based
Vitamin D analogs, escalating to “maximum” safe doses (eg,
   intravenous paricalcitol 15 μg per week, doxercalciferol 7.5 μg per  
   week, or calcitriol 3.75 μg per week, or oral equivalents)
Step 2
Consider addition of cinacalet if:
PTH levels not sufficiently reduced
Calcium levels exceed 9.5 mg/dL
Advantages
Overall superiority of SHPT  
   control
Less hypercalcemia
Probably less risk of vascular 
   calcification
Disadvantages
Risk of hypocalcemia
Poor cinaclacet tolerability in 
  some patients
Expense of cinacalcet
Adherence to oral medications 
  (cinacalcet) not assured
Advantages
Demonstrated survival benefit in 
   retrospective studies (compared 
   to no vitamin D analogs)
Less risk of hypocalcemia
Adherence assured if parenteral 
   activated vitamin D compounds
   administered
Disadvantages
Inferior control of SHPT
Risk of hypercalcemia
May promote vascular
   calcification
Adherence to oral activated vitamin D
   compounds not assured
still maintaining a role for low doses of vitamin D analogs 
to defend against hypocalcemia while contributing poten-
tial non-mineral-metabolism-related survival beneﬁ  ts that 
may be responsible for the ﬁ  ndings of other studies.60,61 In 
a cinacalcet-based approach, doses of activated vitamin D 
analogs can be increased if cinacalcet is ineffective or not 
tolerated at adequate doses. Because of poor tolerability in 
some patients as well as the expense for individuals without 
drug insurance coverage, cinacalcet treatment poses adher-
ence challenges. Nevertheless, the potential beneﬁ  ts of a 
cinacalcet-based strategy, speciﬁ  cally better overall control 
of SHPT, as demonstrated in multiple RCTs, and the likeli-
hood of less hypercalcemia, make this the preferred therapeu-
tic approach at the current time. A vitamin D analog-based 
strategy, in which cinacalet is added only if large doses of 
activated vitamin D is ineffective at controlling PTH or if 
hypercalcemia results, is less likely to lead to optimal SHPT 
control and may lead to a higher risk of vascular calciﬁ  cation 
and, ultimately, mortality. As such, the latter is a less attrac-
tive therapeutic approach for most patients.
Conclusions: time for a new 
treatment paradigm of SHPT 
in ESRD?
Treatment paradigms for SHPT must consider the pathogen-
esis of the disease as well as the results of clinical studies. 
In general, we believe that a cinacalcet-based approach is 
superior for most patients with SHPT because (1) clini-
cal trials have demonstrated the superior suppression of 
PTH and control of Ca × P product in ESRD patients 
with calcimimetics, relative to vitamin D analogs, both 
when used as adjunctive therapy superimposed on vitamin 
D analogs and also as “primary” therapy with low doses 
of vitamin D analogs; (2) decreased levels of calcitriol 
appear to be an adaptive response in advanced renal dis-
ease to limit the toxic effects of hyperphosphatemia; (3) 
molecular human and mouse genetic studies demonstrate the 
greater importance of the CASR, relative to the VDR, in the 
regulation of PTG function; and (4) the use of cinacalcet may 
result in less calcium loading than therapy with vitamin D 
analogs. Calcium loading with calcium-based binders, in the 
setting of concurrent activated vitamin D compound therapy, 
has been associated with increased vascular calciﬁ  cations.4
Although survival beneﬁ  ts of vitamin D analogs in ESRD 
have not been demonstrated in an RCT, such beneﬁ  ts are bio-
logically plausible, and physiological “replacement” doses 
of vitamin D analogs (eg, paricalcitol 2 μg or doxercalciferol 
1 μg thrice weekly) appear warranted in the majority of 
patients without obvious contraindications. In contrast, long-
term use of high-dose vitamin D analogs probably results in 
a more positive Ca balance in ESRD than similar treatment 
with cinacalcet, although studies that assess the risk reduction International Journal of Nephrology and Renovascular Disease 2008:1 14
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of cinacalcet currently exist solely in animal models.110 
Low doses of vitamin D analogs, as adjunctive therapy to cina-
calet, are likely to emerge as the standard of care. These tonic 
doses of activated vitamin D therapy could be increased when 
(1) calcimimetics have been tried at maximal doses and failed 
to control SHPT, (2) calcimimetics have intolerable side effects 
at effective doses, or (3) calcimimetic use results in hypocal-
cemia, an effect which can frequently be remedied by vitamin 
D analogs. Whether nutritional vitamin D supplementation, 
in addition to treatment with activated vitamin D compounds, 
is of beneﬁ  t is uncertain at the current time.
The nephrology community has dire need for data from 
well-designed RCTs to determine whether calcimimetics 
provide mortality beneﬁ  ts relative to vitamin D analogs. 
While a study in which cinacalcet is tested directly against 
a vitamin D analog would provides for a more rigorous 
experimental design, widespread use of vitamin D analogs, as 
well as their beneﬁ  t in protection against cinacalcet-induced 
hypocalcemia, probably makes employment of such a design 
impractical. However, a trial in which low-dose vitamin D ana-
logs are administered in the cinacalet arm would reﬂ  ect clini-
cal practice realities and increase the likelihood that subjects 
randomized to cinacalcet would be consistently exposed to 
the drug over a lengthy treatment period, a likely requirement 
if the trial is to show unambiguous differences in cumulative 
event rates. In the absence of clinical trial data, calcimimetics, 
along with dietary phosphate control, should be considered 
primary therapy in most ESRD patients with SHPT.
Disclosures
JBW receives honoraria and research funding from Amgen, 
Inc. LDQ receives honoraria from, and serves on the advisory 
board of, Amgen, Inc.
References
  1.  Block GA, Hulbert-Shearon TE, Levin NW, Port FK. Association of 
serum phosphorus and calcium × phosphate product with mortality risk 
in chronic hemodialysis patients: a national study. Am J Kidney Dis. 
1998;31(4):607–617.
 2. Ganesh SK, Stack AG, Levin NW, Hulbert-Shearon T, Port FK. 
Association of elevated serum PO(4), Ca × PO(4) product, and para-
thyroid hormone with cardiac mortality risk in chronic hemodialysis 
patients. J Am Soc Nephrol. 2001;12(10):2131–2138.
  3.  Goodman WG, Goldin J, Kuizon BD, Yoon C, Gales B, Sider D, et al. 
Coronary-artery calciﬁ  cation in young adults with end-stage renal disease 
who are undergoing dialysis. N Engl J Med. 2000;342(20):1478–1483.
  4.  Chertow GM, Burke SK, Raggi P. Sevelamer attenuates the progression 
of coronary and aortic calciﬁ  cation in hemodialysis patients. Kidney 
Int. 2002;62(1):245–252.
 5. Chertow GM, Raggi P, McCarthy JT, Schulman G, Silberzweig J, 
Kuhlik A, et al. The effects of sevelamer and calcium acetate on proxies 
of atherosclerotic and arteriosclerotic vascular disease in hemodialysis 
patients. Am J Nephrol. 2003;23(5):307–314.
 6. Ferramosca E, Burke S, Chasan-Taber S, Ratti C, Chertow GM, 
Raggi P. Potential antiatherogenic and anti-inﬂ  ammatory properties 
of sevelamer in maintenance hemodialysis patients. Am Heart J. 
2005;149(5):820–825.
  7.  Block GA, Spiegel DM, Ehrlich J, Mehta R, Lindbergh J, Dreisbach A, 
et al. Effects of sevelamer and calcium on coronary artery calciﬁ  cation 
in patients new to hemodialysis. Kidney Int. 2005;68(4):1815–1824.
  8.  Goodman WG, Hladik GA, Turner SA, Blaisdell PW, Goodkin DA, Liu W, 
et al. The Calcimimetic agent AMG 073 lowers plasma parathyroid 
hormone levels in hemodialysis patients with secondary hyperpara-
thyroidism. J Am Soc Nephrol. 2002;13(4):1017–1024.
  9.  Quarles LD, Sherrard DJ, Adler S, Rosansky SJ, McCary LC, Liu W, 
et al. The calcimimetic AMG 073 as a potential treatment for secondary 
hyperparathyroidism of end-stage renal disease. J Am Soc Nephrol. 
2003;14(3):575–583.
10.  Lindberg JS, Moe SM, Goodman WG, Coburn JW, Sprague SM, Liu W, 
et al. The calcimimetic AMG 073 reduces parathyroid hormone and 
calcium × phosphorus in secondary hyperparathyroidism. Kidney Int. 
2003;63(1):248–254.
11.  Lindberg JS, Culleton B, Wong G, Borah MF, Clark RV, Shapiro WB, 
et al. Cinacalcet HCl, an oral calcimimetic agent for the treatment of 
secondary hyperparathyroidism in hemodialysis and peritoneal dialysis: 
a randomized, double-blind, multicenter study. J Am Soc Nephrol. 
2005;16(3):800–807.
12. Block GA, Martin KJ, de Francisco AL, Turner SA, Avram MM, 
Suranyi MG, et al. Cinacalcet for secondary hyperparathyroidism 
in patients receiving hemodialysis. N Engl J Med. 2004;350(15):1516–1525.
13. Strippoli GF, Palmer S, Tong A, Elder G, Messa P, Craig JC. 
Meta-analysis of biochemical and patient-level effects of calcimimetic 
therapy. Am J Kidney Dis. 2006;47(5):715–726.
14.  Martin KJ, Juppner H, Sherrard DJ, Goodman WG, Kaplan MR, 
Nassar G, et al. First- and second-generation immunometric PTH assays 
during treatment of hyperparathyroidism with cinacalcet HCl. Kidney 
Int. 2005;68(3):1236–1243.
15.  Fukagawa M, Yumita S, Akizawa T, Uchida E, Tsukamoto Y, 
Iwasaki M, et al. Cinacalcet (KRN1493) effectively decreases the serum 
intact PTH level with favorable control of the serum phosphorus and 
calcium levels in Japanese dialysis patients. Nephrol Dial Transplant. 
2008;23(1):328–335.
16.  Messa P, Macario F, Yaqoob M, Bouman K, Braun J, von Albertini B, 
et al.  The OPTIMA study: assessing a new cinacalcet (Sensipar/Mimpara) 
treatment algorithm for secondary hyperparathyroidism. Clin J Am Soc 
Nephrol. 2008;3(1):36–45.
17.  Moe SM, Cunningham J, Bommer J, Adler S, Rosansky SJ, Urena-Torres P, 
et al. Long-term treatment of secondary hyperparathyroidism with the 
calcimimetic cinacalcet HCl. Nephrol Dial Transplant. 2005;20(10): 
2186–2193.
18. Sterrett JR, Strom J, Stummvoll HK, Bahner U, Disney A, Soroka 
SD, et al. Cinacalcet HCI (Sensipar/Mimpara) is an effective chronic 
therapy for hemodialysis patients with secondary hyperparathyroidism. 
Clin Nephrol. 2007;68(1):10–17.
19.  Chertow GM, Blumenthal S, Turner S, Roppolo M, Stern L, Chi EM, 
et al. Cinacalcet hydrochloride (Sensipar) in hemodialysis patients on 
active vitamin D derivatives with controlled PTH and elevated calcium × 
phosphate. Clin J Am Soc Nephrol. 2006;1(2):305–312.
20.  Block GA, Zeig S, Sugihara J, Chertow GM, Chi EM, Turner SA, et al. 
Combined therapy with cinacalcet and low doses of vitamin D sterols 
in patients with moderate to severe secondary hyperparathyroidism. 
Nephrol Dial Transplant. 2008. In press.
21.  Arenas MD, Alvarez-Ude F, Gil MT, Moledous A, Malek T, Nunez C, 
et al. Implementation of ‘K/DOQI Clinical Practice Guidelines for Bone 
Metabolism and Disease in Chronic Kidney Disease’ after the introduc-
tion of cinacalcet in a population of patients on chronic haemodialysis. 
Nephrol Dial Transplant. 2007;22(6):1639–1644.
22.  Lazar E, Hebert K, Poma T, Stankus N. Long-term outcomes of cina-
calcet and paricalcitol titration protocol for treatment of secondary 
hyperparathyroidism. Am J Nephrol. 2007;27(3):274–278.International Journal of Nephrology and Renovascular Disease 2008:1 15
Calcimimetics and vitamin D analogs in kidney disease
23.  Spiegel DM, Casey L, Bell S, Parker M, Chonchol M. Achieving 
targets for bone and mineral metabolism: the impact of cinacalcet HCl 
in clinical practice. Hemodial Int. 2006;10(Suppl 2):S24–27.
24.  Brown EM, MacLeod RJ. Extracellular calcium sensing and extracel-
lular calcium signaling. Physiol Rev. 2001;81(1):2392–97.
25. Brown EM. Clinical lessons from the calcium-sensing receptor. Nat 
Clin Pract Endocrinol Metab. 2007;3(2):122–133.
26.  Silver J, Levi R. Regulation of PTH synthesis and secretion relevant to 
the management of secondary hyperparathyroidism in chronic kidney 
disease. Kidney Int Suppl. 2005;(95):S8–12.
27.  Pollak MR, Brown EM, Chou YH, Hebert SC, Marx SJ, Steinmann B, 
et al. Mutations in the human Ca(2+)−sensing receptor gene cause 
familial hypocalciuric hypercalcemia and neonatal severe hyperpara-
thyroidism. Cell. 1993;75(7):1297–1303.
28. Ho C, Conner DA, Pollak MR, Ladd DJ, Kifor O, Warren HB, 
et al. A mouse model of human familial hypocalciuric hypercal-
cemia and neonatal severe hyperparathyroidism. Nat Genet. 1995;
11(4):389–394.
29.  Gogusev J, Duchambon P, Hory B, Giovannini M, Goureau Y, 
Sarfati E, et al. Depressed expression of calcium receptor in parathy-
roid gland tissue of patients with hyperparathyroidism. Kidney Int. 
1997;51(1):328–336.
30.  Kifor O, Moore FD, Jr, Wang P, Goldstein M, Vassilev P, Kifor I, et al. 
Reduced immunostaining for the extracellular Ca2+-sensing receptor in 
primary and uremic secondary hyperparathyroidism. J Clin Endocrinol 
Metab. 1996;81(4):1598–1606.
31.  Brown AJ, Ritter CS, Finch JL, Slatopolsky EA. Decreased calcium-
sensing receptor expression in hyperplastic parathyroid glands 
of uremic rats: role of dietary phosphate. Kidney Int. 1999;55(4):
1284–1292.
32. Ritter CS, Finch JL, Slatopolsky EA, Brown AJ. Parathyroid hyperplasia 
in uremic rats precedes down-regulation of the calcium receptor. Kidney 
Int. 2001;60(5):1737–1744.
33. Drueke T, Martin D, Rodriguez M. Can calcimimetics inhibit para-
thyroid hyperplasia? Evidence from preclinical studies. Nephrol Dial 
Transplant. 2007;22(7):1828–1839.
34. Colloton  M,  Shatzen E, Miller G, Stehman-Breen C, Wada M, Lacey D, 
et al. Cinacalcet HCl attenuates parathyroid hyperplasia in a rat model 
of secondary hyperparathyroidism. Kidney Int. 2005;67(2):467–476.
35. Chin  J, Miller SC, Wada M, Nagano N, Nemeth EF, Fox J. Activation of 
the calcium receptor by a calcimimetic compound halts the progression 
of secondary hyperparathyroidism in uremic rats. J Am Soc Nephrol. 
2000;11(5):903–911.
36.  Mizobuchi M, Hatamura I, Ogata H, Saji F, Uda S, Shiizaki K, et al. 
Calcimimetic compound upregulates decreased calcium-sensing 
receptor expression level in parathyroid glands of rats with chronic 
renal insufﬁ  ciency. J Am Soc Nephrol. 2004;15(10):2579–2587.
37.  de Francisco AL, Izquierdo M, Cunningham J, Pinera C, Palomar R, 
Fresnedo GF, et al. Calcium-mediated parathyroid hormone release 
changes in patients treated with the calcimimetic agent cinacalcet. 
Nephrol Dial Transplant. 2008 Apr 23.
38.  Lomonte C, Vernaglione L, Chimienti D, Bruno A, Cocola S, 
Teutonico A, et al. Does vitamin D receptor and calcium receptor 
activation therapy play a role in the histopathologic alterations of 
parathyroid glands in refractory uremic hyperparathyroidism? Clin J 
Am Soc Nephrol. 2008;3(3):794–799.
39. Yamaguchi S, Yachiku S, Morikawa M. Analysis of proliferative 
activity of the parathyroid glands using proliferating cell nuclear 
antigen in patients with hyperparathyroidism. J Clin Endocrinol Metab. 
1997;82(8):2681–268.
40.  Malluche HH, Monier-Faugere MC, Wang G, Fraza OJ, Charytan C, 
Coburn JW, et al. An assessment of cinacalcet HCl effects on bone 
histology in dialysis patients with secondary hyperparathyroidism. Clin 
Nephrol. 2008;69(4):269–278.
41.  Wang R, Xu C, Zhao W, Zhang J, Cao K, Yang B, et al. Calcium and 
polyamine regulated calcium-sensing receptors in cardiac tissues. Eur 
J Biochem. 2003;270(12):2680–268.
42.  Tfelt-Hansen J, Hansen JL, Smajilovic S, Terwilliger EF, Haunso S, 
Sheikh SP. Calcium receptor is functionally expressed in rat neonatal 
ventricular cardiomyocytes. Am J Physiol Heart Circ Physiol. 
2006;290(3):H1165–1171.
43.  Farzaneh-Far A, Proudfoot D, Weissberg PL, Shanahan CM. 
Matrix gla protein is regulated by a mechanism functionally related 
to the calcium-sensing receptor. Biochem Biophys Res Commun. 
2000;277(3):736–740.
44. Wang Y, Bukoski RD. Distribution of the perivascular nerve Ca2+ 
receptor in rat arteries. Br J Pharmacol. 1998;125(7):1397–1404.
45.  Wonneberger K, Scoﬁ  eld MA, Wangemann P. Evidence for a calcium-
sensing receptor in the vascular smooth muscle cells of the spiral 
modiolar artery. J Membr Biol. 2000;175(3):203–212.
46. Smajilovic S, Hansen JL, Christoffersen TE, Lewin E, Sheikh SP, 
Terwilliger EF, et al. Extracellular calcium sensing in rat aortic 
vascular smooth muscle cells. Biochem Biophys Res Commun. 
2006;348(4):1215–1223.
47. Ziegelstein RC, Xiong Y, He C, Hu Q. Expression of a functional 
extracellular calcium-sensing receptor in human aortic endothelial 
cells. Biochem Biophys Res Commun. 2006;342(1):153–163.
48.  Smajilovic S, Tfelt-Hansen J. Calcium acts as a ﬁ  rst messenger through 
the calcium-sensing receptor in the cardiovascular system. Cardiovasc 
Res. 2007;75(3):457–467.
49.  Ogata H, Ritz E, Odoni G, Amann K, Orth SR. Beneﬁ  cial effects of 
calcimimetics on progression of renal failure and cardiovascular risk 
factors. J Am Soc Nephrol. 2003;14(4):959–967.
50.  Cunningham J, Danese M, Olson K, Klassen P, Chertow GM. Effects 
of the calcimimetic cinacalcet HCl on cardiovascular disease, fracture, 
and health-related quality of life in secondary hyperparathyroidism. 
Kidney Int. 2005;68(4):1793–1800.
51.  Martin KJ, Gonzalez EA, Gellens M, Hamm LL, Abboud H, Lindberg J. 
19-Nor-1-alpha-25-dihydroxyvitamin D2 (Paricalcitol) safely and effec-
tively reduces the levels of intact parathyroid hormone in patients on 
hemodialysis. J Am Soc Nephrol. 1998;9(8):1427–1432.
52.  Delmez JA, Kelber J, Norwood KY, Giles KS, Slatopolsky E. A con-
trolled trial of the early treatment of secondary hyperparathyroidism with 
calcitriol in hemodialysis patients. Clin Nephrol. 2000;54(4):301–308.
53.  Coyne DW, Grieff M, Ahya SN, Giles K, Norwood K, Slatopolsky E. 
Differential effects of acute administration of 19-Nor-1,25-dihydroxy-
vitamin D2 and 1,25-dihydroxy-vitamin D3 on serum calcium 
and phosphorus in hemodialysis patients. Am J Kidney Dis. 
2002;40(6):1283–1288.
54.  Joist HE, Ahya SN, Giles K, Norwood K, Slatopolsky E, Coyne DW. 
Differential effects of very high doses of doxercalciferol and parical-
citol on serum phosphorus in hemodialysis patients. Clin Nephrol. 
2006;65(5):335–341.
55.  Sprague SM, Llach F, Amdahl M, Taccetta C, Batlle D. Paricalcitol 
versus calcitriol in the treatment of secondary hyperparathyroidism. 
Kidney Int. 2003;63(4):1483–1490.
56.  Brandi L, Daugaard H, Tvedegaard E, Nielsen PK, Egsmose C, Storm T, 
et al. Long-term suppression of secondary hyperparathyroidism by 
intravenous 1 alpha-hydroxyvitamin D3 in patients on chronic hemo-
dialysis. Am J Nephrol. 1992;12(5):311–318.
57. Lindberg J, Martin KJ, Gonzalez EA, Acchiardo SR, Valdin JR, 
Soltanek C. A long-term, multicenter study of the efficacy and 
safety of paricalcitol in end-stage renal disease. Clin Nephrol. 
2001;56(4):315–323.
58.  Akizawa T, Suzuki M, Akiba T, Nishizawa Y, Ohashi Y, Ogata E, et al. 
Long-term effect of 1,25-dihydroxy-22-oxavitamin D(3) on secondary 
hyperparathyroidism in haemodialysis patients. One-year administration 
study. Nephrol Dial Transplant. 2002;(17 Suppl 10):28–36.
59. Teng M, Wolf M, Lowrie E, Ofsthun N, Lazarus JM, Thadhani R. 
Survival of patients undergoing hemodialysis with paricalcitol or 
calcitriol therapy. N Engl J Med. 2003;349(5):446–456.
60. Teng  M, Wolf M, Ofsthun MN, Lazarus JM, Hernan MA, Camargo CA, 
Jr, et al. Activated injectable vitamin D and hemodialysis survival: a 
historical cohort study. J Am Soc Nephrol. 2005;16(4):1115–1125.International Journal of Nephrology and Renovascular Disease 2008:1 16
Wetmore and Quarles
61.  Kalantar-Zadeh K, Kuwae N, Regidor DL, Kovesdy CP, Kilpatrick RD, 
Shinaberger CS, et al. Survival predictability of time-varying indica-
tors of bone disease in maintenance hemodialysis patients. Kidney Int. 
2006;70(4):771–780.
62.  Tentori F, Hunt WC, Stidley CA, Rohrscheib MR, Bedrick EJ, 
Meyer KB, et al. Mortality risk among hemodialysis patients receiving 
different vitamin D analogs. Kidney Int. 2006;70(10):1858–1865.
63.  Al-Badr W, Martin KJ. Vitamin D and Kidney Disease. Clin J Am Soc 
Nephrol. 2008 May 1.
64.  Brown AJ, Slatopolsky E. Drug insight: vitamin D analogs in the treat-
ment of secondary hyperparathyroidism in patients with chronic kidney 
disease. Nat Clin Pract Endocrinol Metab. 2007 Feb;3(2):134–144.
65.  Mehrotra R, Kermah D, Budoff M, Salusky IB, Mao SS, Gao YL, et al. 
Hypovitaminosis D in Chronic Kidney Disease. Clin J Am Soc Nephrol. 
2008 Apr 16.
66.  Zehnder D, Landray MJ, Wheeler DC, Fraser W, Blackwell L, Nuttall S, 
et al. Cross-sectional analysis of abnormalities of mineral homeostasis, 
vitamin D and parathyroid hormone in a cohort of pre-dialysis patients. 
The chronic renal impairment in Birmingham (CRIB) study. Nephron 
Clin Pract. 2007;107(3):c109–16.
67.  Slatopolsky E, Brown A, Dusso A. Role of phosphorus in the 
pathogenesis of secondary hyperparathyroidism. Am J Kidney Dis. 
2001 Jan;37(1 Suppl 2):S54–7.
68.  Rowe PS. The wrickkened pathways of FGF23, MEPE and PHEX. Crit 
Rev Oral Biol Med. 2004;15(5):264–281.
69.  Zisman AL, Hristova M, Ho LT, Sprague SM. Impact of ergocalciferol 
treatment of vitamin D deﬁ  ciency on serum parathyroid hormone concen-
trations in chronic kidney disease. Am J Nephrol. 2007;27(1):36–43.
70.  Al-Aly Z, Qazi RA, Gonzalez EA, Zeringue A, Martin KJ. Changes in 
serum 25-hydroxyvitamin D and plasma intact PTH levels following 
treatment with ergocalciferol in patients with CKD. Am J Kidney Dis. 
2007;50(1):59–68.
71.  Chandra P, Binongo JN, Ziegler TR, Schlanger LE, Wang W, 
Someren JT, et al. Cholecalciferol (vitamin D3) therapy and vitamin D 
insufﬁ  ciency in patients with chronic kidney disease: a randomized 
controlled pilot study. Endocr Pract. 2008;14(1):10–17.
72. Saito H, Kusano K, Kinosaki M, Ito H, Hirata M, Segawa H, et al. 
Human ﬁ  broblast growth factor-23 mutants suppress Na+−dependent 
phosphate co-transport activity and 1alpha, 25-dihydroxyvitamin D3 
production. J Biol Chem. 2003;278(4):2206–2211.
73.  Liu S, Tang W, Zhou J, Stubbs JR, Luo Q, Pi M, et al. Fibroblast growth 
factor 23 is a counter-regulatory phosphaturic hormone for vitamin D. 
J Am Soc Nephrol. 2006 May;17(5):1305–1315.
74.  Krajisnik T, Bjorklund P, Marsell R, Ljunggren O, Akerstrom G, 
Jonsson KB, et al. Fibroblast growth factor-23 regulates parathyroid 
hormone and 1alpha-hydroxylase expression in cultured bovine para-
thyroid cells. J Endocrinol. 2007;195(1):125–131.
75.  Shimada T, Hasegawa H, Yamazaki Y, Muto T, Hino R, Takeuchi Y, 
et al. FGF-23 is a potent regulator of vitamin D metabolism and phos-
phate homeostasis. J Bone Miner Res. 2004;19(3):429–435.
76.  Perwad F, Zhang MY, Tenenhouse HS, Portale AA. Fibroblast growth 
factor 23 impairs phosphorus and vitamin D metabolism in vivo and 
suppresses 25-hydroxyvitamin D-1alpha-hydroxylase expression 
in vitro. Am J Physiol Renal Physiol. 2007;293(5):F1577–1583.
77.  Larsson T, Nisbeth U, Ljunggren O, Juppner H, Jonsson KB. Circulat-
ing concentration of FGF-23 increases as renal function declines in 
patients with chronic kidney disease, but does not change in response 
to variation in phosphate intake in healthy volunteers. Kidney Int. 
2003;64(6):2272–2279.
78. Shigematsu T, Kazama JJ, Yamashita T, Fukumoto S, Hosoya T, Gejyo F, 
et al. Possible involvement of circulating ﬁ  broblast growth factor 23 
in the development of secondary hyperparathyroidism associated with 
renal insufﬁ  ciency. Am J Kidney Dis. 2004;44(2):250–256.
79.  Gutierrez O, Isakova T, Rhee E, Shah A, Holmes J, Collerone G, et al. 
Fibroblast growth factor-23 mitigates hyperphosphatemia but accentu-
ates calcitriol deﬁ  ciency in chronic kidney disease. J Am Soc Nephrol. 
2005;16(7):2205–2215.
80.  Coburn JW, Maung HM, Elangovan L, Germain MJ, Lindberg 
JS, Sprague SM, et al. Doxercalciferol safely suppresses PTH 
levels in patients with secondary hyperparathyroidism associated 
with chronic kidney disease stages 3 and 4. Am J Kidney Dis. 
2004;43(5):877–890.
81. Goodman WG. Calcimimetics: a remedy for all problems of excess 
parathyroid hormone activity in chronic kidney disease? Curr Opin 
Nephrol Hypertens. 2005;14(4):355–360.
82. Kos CH, Karaplis AC, Peng JB, Hediger MA, Goltzman D, 
Mohammad KS, et al. The calcium-sensing receptor is required for 
normal calcium homeostasis independent of parathyroid hormone. 
J Clin Invest. 2003;111(7):1021–1028.
83.  Tu Q, Pi M, Karsenty G, Simpson L, Liu S, Quarles LD. Rescue of the 
skeletal phenotype in CasR-deﬁ  cient mice by transfer onto the Gcm2 
null background. J Clin Invest. 2003;111(7):1029–37.
84. Li YC, Amling M, Pirro AE, Priemel M, Meuse J, Baron R, 
et al. Normalization of mineral ion homeostasis by dietary means 
prevents hyperparathyroidism, rickets, and osteomalacia, but 
not alopecia in vitamin D receptor-ablated mice. Endocrinology. 
1998;139(10):4391–4396.
85. Martin LN, Kayath MJ, Vieira JG, Nose-Alberti V. Parathyroid 
glands in uraemic patients with refractory hyperparathyroidism: 
histopathology and p53 protein expression analysis. Histopathology. 
1998;33(1):46–51.
86.  Fukuda N, Tanaka H, Tominaga Y, Fukagawa M, Kurokawa K, Seino Y. 
Decreased 1,25-dihydroxyvitamin D3 receptor density is associated 
with a more severe form of parathyroid hyperplasia in chronic uremic 
patients. J Clin Invest. 1993;92(3):1436–1443.
87.  Wang X, Sun B, Zhou F, Hu J, Yu X, Peng T. Vitamin D receptor and 
PCNA expression in severe parathyroid hyperplasia of uremic patients. 
Chin Med J (Engl). 2001;114(4):410–414.
88.  Tokumoto M, Tsuruya K, Fukuda K, Kanai H, Kuroki S, Hirakata H. 
Reduced p21, p27 and vitamin D receptor in the nodular hyperplasia 
in patients with advanced secondary hyperparathyroidism. Kidney Int. 
2002;62(4):1196–1207.
89. Yano S, Sugimoto T, Tsukamoto T, Chihara K, Kobayashi A, 
Kitazawa S, et al. Decrease in vitamin D receptor and calcium-sensing 
receptor in highly proliferative parathyroid adenomas. Eur J Endocrinol. 
2003;148(4):403–411.
90. Brown AJ, Zhong M, Finch J, Ritter C, McCracken R, Morrissey J, 
et al. Rat calcium-sensing receptor is regulated by vitamin D but not 
by calcium. Am J Physiol. 1996;270(3 Pt 2):F454–460.
91.  Canaff L, Hendy GN. Human calcium-sensing receptor gene. 
Vitamin D response elements in promoters P1 and P2 confer tran-
scriptional responsiveness to 1,25-dihydroxyvitamin D. J Biol Chem. 
2002;277(33):30337–30350.
92.  Tokumoto M, Taniguchi M, Matsuo D, Tsuruya K, Hirakata H, Iida M. 
Parathyroid cell growth in patients with advanced secondary hyper-
parathyroidism: vitamin D receptor, calcium sensing receptor, and 
cell cycle regulating factors. Ther Apher Dial. 2005;9(Suppl 1):
S27–34.
93.  Liu PT, Stenger S, Li H, Wenzel L, Tan BH, Krutzik SR, et al. Toll-
like receptor triggering of a vitamin D-mediated human antimicrobial 
response. Science. 2006;311(5768):1770–1773.
94.  Peterlik M, Cross HS. Vitamin D and calcium deﬁ  cits predispose for 
multiple chronic diseases. Eur J Clin Invest. 2005;35(5):290–304.
95.  Girasole G, Wang JM, Pedrazzoni M, Pioli G, Balotta C, Passeri M, et al. 
Augmentation of monocyte chemotaxis by 1 alpha, 25-dihydroxyvitamin D3. 
Stimulation of defective migration of AIDS patients. J Immunol. 
1990;145(8):2459–2464.
96.  Provvedini DM, Deftos LJ, Manolagas SC. 1,25-Dihydroxyvitamin D3 
promotes in vitro morphologic and enzymatic changes in normal human 
monocytes consistent with their differentiation into macrophages. Bone. 
1986;7(1):23–28.
97.  Orikasa M, Kawase T, Suzuki A. Induction of macrophagic and 
granulocytic differentiation of murine bone marrow progenitor cells by 
1,25-dihydroxyvitamin D3. Calcif Tissue Int. 1993;53(3):193–200.International Journal of Nephrology and Renovascular Disease 2008:1 17
Calcimimetics and vitamin D analogs in kidney disease
  98.  Boltz-Nitulescu G, Willheim M, Spittler A, Leutmezer F, Tempfer C, 
Winkler S. Modulation of IgA, IgE, and IgG Fc receptor expression on 
human mononuclear phagocytes by 1 alpha,25-dihydroxyvitamin D3 
and cytokines. J Leukoc Biol. 1995;58(2):256–262.
  99.  Cohen MS, Mesler DE, Snipes RG, Gray TK. 1,25-Dihydroxyvitamin 
D3 activates secretion of hydrogen peroxide by human monocytes. 
J Immunol. 1986;136(3):1049–1053.
100.  Sly LM, Lopez M, Nauseef WM, Reiner NE. 1alpha, 25-
Dihydroxyvitamin D3-induced monocyte antimycobacterial 
activity is regulated by phosphatidylinositol 3-kinase and medi-
ated by the NADPH-dependent phagocyte oxidase. J Biol Chem. 
2001;276(38):35482–35493.
101. Nnoaham KE, Clarke A. Low serum vitamin D levels and tuber-
culosis: a systematic review and meta-analysis. Int J Epidemiol. 
2008;37(1):113–119.
102.  Gallieni M, Kamimura S, Ahmed A, Bravo E, Delmez J, Slatopolsky 
E, et al. Kinetics of monocyte 1 alpha-hydroxylase in renal failure. 
Am J Physiol. 1995;268(4 Pt 2):F746–753.
103. Pereira MA, Jacobs DR Jr, Van Horn L, Slattery ML, Kartashov AI, 
Ludwig DS. Dairy consumption, obesity, and the insulin resis-
tance syndrome in young adults: the CARDIA Study. JAMA. 
2002;287(16):2081–2089.
104. Ford ES, Ajani UA, McGuire LC, Liu S. Concentrations of serum 
vitamin D and the metabolic syndrome among US adults. Diabetes 
Care. 2005;28(5):1228–1230.
105.  Liu S, Song Y, Ford ES, Manson JE, Buring JE, Ridker PM. Dietary cal-
cium, vitamin D, and the prevalence of metabolic syndrome in middle-
aged and older US women. Diabetes Care. 2005;28(12):2926–2932.
106.  Wu J, Garami M, Cheng T, Gardner DG. 1,25(OH)2 vitamin D3, and 
retinoic acid antagonize endothelin-stimulated hypertrophy of neonatal 
rat cardiac myocytes. J Clin Invest. 1996;97(7):1577–1588.
107.  Li YC, Kong J, Wei M, Chen ZF, Liu SQ, Cao LP. 1,25-Dihydroxyvi-
tamin D(3) is a negative endocrine regulator of the renin-angiotensin 
system. J Clin Invest. 2002;110(2):229–238.
108. Spiegel DM, Raggi P, Smits G, Block GA. Factors associated with 
mortality in patients new to haemodialysis. Nephrol Dial Transplant. 
2007;22(12):3568–3572.
109.  Block GA, Raggi P, Bellasi A, Kooienga L, Spiegel DM. Mortality 
effect of coronary calciﬁ  cation and phosphate binder choice in incident 
hemodialysis patients. Kidney Int. 2007;71(5):438–441.
110. Lopez I, Mendoza FJ, Aguilera-Tejero E, Perez J, Guerrero F, 
Martin D, et al. The effect of calcitriol, paricalcitol, and a calci-
mimetic on extraosseous calciﬁ  cations in uremic rats. Kidney Int. 
2008;73(3):300–307.